Is Eagle Pharmaceuticals Inc (EGRX) Stock About to Get Hot Monday?

Eagle Pharmaceuticals Inc (EGRX) stock is down 5.33% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Eagle Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EGRX!

See Full EGRX Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With EGRX Stock Today?

Eagle Pharmaceuticals Inc (EGRX) stock is down -10.08% while the S&P 500 is higher by 0.26% as of 12:03 PM on Monday, Jun 5. EGRX has fallen -$2.17 from the previous closing price of $21.53 on volume of 104,079 shares. Over the past year the S&P 500 is higher by 4.18% while EGRX has fallen -58.79%. EGRX lost -$0.22 per share in the over the last 12 months. To screen for more stocks like Eagle Pharmaceuticals Inc click here.

More About Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. Click Here to get the full Stock Report for Eagle Pharmaceuticals Inc stock.